← Leaderboards
Glen Andrew Coburn
Progenics Pharmaceuticals, Inc.
$12,617,543
Attributed
$12,617,543
Total exposure
9
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $2.3M · FY2005–25$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$12,617,543 · 9
By mechanism
R44$9,029,043 · 3
R43$3,588,500 · 6
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Series”
- Lawrence Corey · Fred Hutchinson Cancer Center$445,660,381
- Kiran Datta · Leidos Biomedical Research, Inc.$292,634,066
- David R. Weir · University Of Michigan At Ann Arbor$276,156,779
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$231,733,045
- Dennis R. Burton · Scripps Research Institute$199,946,411
- Joel A Lipkin · Four Points Technology, Llc$183,862,844
Research focus
SeriesSmall Business Innovation Research GrantPropertyLeadDrug KineticsViralDosePharmaceutical PreparationsHigh Throughput ScreeningInfectionProgramsAntiviral AgentsVirusVaccinesOralSuccessSmall MoleculeLibrariesCytotoxicityCandidate SelectionPharmaceutical ChemistryEvaluationToxic EffectVirus Diseases
Grant awards (21)
Optimization of orally bioavailable inhibitors for the treatment of COVID-19 and other human coronavirus infections$999,998
R44 · FY2025 · AI · contact PI
Optimization of orally bioavailable inhibitors for the treatment of COVID-19 and other human coronavirus infections$1,000,000
R44 · FY2024 · AI · contact PI
Discovery of antiviral inhibitors for the treatment of orthopoxvirus infections$300,000
R43 · FY2024 · AI · contact PI
Preclinical development of capsid assembly modulators for the treatment of chronic hepatitis B virus infection$1,000,000
R44 · FY2023 · AI · contact PI
Optimization of orally bioavailable inhibitors for the treatment of COVID-19 and other human coronavirus infections$1,000,000
R44 · FY2023 · AI · contact PI
Discovery of antiviral inhibitors for the treatment of orthopoxvirus infections$300,000
R43 · FY2023 · AI · contact PI
Preclinical development of capsid assembly modulators for the treatment of chronic hepatitis B virus infection$1,000,000
R44 · FY2022 · AI · contact PI
Discovery of inhibitors that target HBx for the treatment of chronic HBV infection$253,810
R43 · FY2022 · AI · contact PI
Preclinical development of capsid assembly modulators for the treatment of chronic hepatitis B virus infection$1,000,000
R44 · FY2021 · AI · contact PI
Discovery of antiviral inhibitors of Ebola virus replication$300,000
R43 · FY2021 · AI · contact PI
Discovery of inhibitors that target HBx for the treatment of chronic HBV infection$252,813
R43 · FY2021 · AI · contact PI
Discovery of antiviral inhibitors of Ebola virus replication$300,000
R43 · FY2020 · AI · contact PI
Discovery of inhibitors of Zika virus$299,999
R43 · FY2018 · AI · contact PI
Discovery of inhibitors of BK polyomavirus$343,497
R43 · FY2017 · AI · contact PI
Discovery of inhibitors of Zika virus$299,999
R43 · FY2017 · AI · contact PI
Discovery of inhibitors of BK polyomavirus$347,101
R43 · FY2016 · AI · contact PI
Novel small-molecule inhibitors of HIV-1 Vif$300,000
R43 · FY2008 · AI · contact PI
Development of Hepatitis C Virus Inhibitors$1,030,553
R44 · FY2007 · AI · contact PI
Novel small-molecule inhibitors of HIV-1 Vif$291,281
R43 · FY2007 · AI · contact PI
Development of Hepatitis C Virus Inhibitors$1,001,572
R44 · FY2006 · AI · contact PI
Development of Hepatitis C Virus Inhibitors$996,920
R44 · FY2005 · AI